5 Psychiatry Headlines You Missed in August 2025

August brought significant developments across the psychiatric landscape, spanning regulatory designations, phase 2 trial results, real-world data, and renewed concerns about alternative therapies. From the FDA granting NRX-100 Fast Track designation for suicidal ideation, to promising phase 2 findings with RE104 in postpartum depression, to esketamine’s role in reducing anhedonia, advances in therapeutic strategies are reshaping the field. Meanwhile, real-world analyses shed light on ADHD medications’ protective effects, while safety data continue to caution against kratom use.